Gasiorek A, Heydorn A, Gabery S et al (2025) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
This complex induces an increase in the expression of pro-apoptotic proteins such as Bax and Bad, and decreases other anti-apoptotic proteins such as Bcl-2 and Bax [46]
Targeting a G-Protein-Coupled receptor overexpressed in endocrine tumors by magnetic nanoparticles to induce cell death
Tracking and iteration : checking your labs, symptoms, weight, energy levels so we can adjust protocols quickly if something isnt working
Use daily for consistent results